MorphoSys AG (WBO:MOR) Forward Dividend Yield % : 0.00% (As of Apr. 28, 2024)

View and export this data going back to 2017. Start your Free Trial

What is MorphoSys AG Forward Dividend Yield %?

As of today (2024-04-28), the Forward Annual Dividend Yield of MorphoSys AG is 0.00%.

As of today (2024-04-28), the Trailing Annual Dividend Yield of MorphoSys AG is 0.00%.

WBO:MOR's Forward Dividend Yield % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.56
* Ranked among companies with meaningful Forward Dividend Yield % only.

MorphoSys AG's Dividends per Share for the three months ended in Dec. 2023 was €0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of MorphoSys AG's Forward Dividend Yield %

For the Biotechnology subindustry, MorphoSys AG's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MorphoSys AG's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MorphoSys AG's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where MorphoSys AG's Forward Dividend Yield % falls into.

MorphoSys AG Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

MorphoSys AG (WBO:MOR) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

MorphoSys AG Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of MorphoSys AG's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

MorphoSys AG (WBO:MOR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MorphoSys AG (WBO:MOR) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

MPSYF:USA MOR:USA 1MOR:Italy MORd:UK 0NDV:UK MOR:Germany

Address

Semmelweisstrasse 7, Planegg, BY, DEU, 82152

Website

https://www.morphosys.com

MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.